Regeneron Pharmaceuticals, Inc. $REGN Holdings Reduced by Horizon Investments LLC

Horizon Investments LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 79.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,892 shares of the biopharmaceutical company’s stock after selling 15,137 shares during the period. Horizon Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $3,004,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Essex Bank bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $213,000. Robertson Stephens Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $491,000. Nkcfo LLC bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $110,000. Fifth Third Bancorp boosted its holdings in shares of Regeneron Pharmaceuticals by 27.9% in the fourth quarter. Fifth Third Bancorp now owns 15,425 shares of the biopharmaceutical company’s stock valued at $11,906,000 after acquiring an additional 3,362 shares in the last quarter. Finally, Danske Bank A S boosted its holdings in shares of Regeneron Pharmaceuticals by 78.8% in the fourth quarter. Danske Bank A S now owns 99,302 shares of the biopharmaceutical company’s stock valued at $76,648,000 after acquiring an additional 43,775 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 1.1%

REGN stock opened at $709.21 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The firm has a market cap of $74.98 billion, a PE ratio of 17.28, a P/E/G ratio of 1.60 and a beta of 0.30. The firm has a 50 day simple moving average of $756.81 and a 200 day simple moving average of $737.56. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same period in the prior year, the business earned $8.22 earnings per share. The business’s quarterly revenue was up 19.0% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.05 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Wall Street Analysts Forecast Growth

REGN has been the subject of several recent analyst reports. Royal Bank Of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating for the company in a report on Thursday, April 30th. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $800.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Evercore increased their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. Finally, Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $826.59.

Insider Activity at Regeneron Pharmaceuticals

In related news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 3,874 shares of company stock valued at $3,013,262 over the last ninety days. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.